# OnCo record cd96 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/cd96/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "cd96" ;
  schema:name "CD96"@en ;
  schema:alternateName "TACTILE"@en, "CD96 molecule"@en, "T-cell surface protein tactile"@en, "CD96" ;
  schema:description "CD96 sits on T and NK cells and binds CD155, the same molecule TIGIT reads on tumour cells. It is the least tested of that family; one blocking antibody is in phase 2 platform trials in lung cancer."@en ;
  schema:url <https://onco.cc/targets/cd96/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16892>, <https://www.uniprot.org/uniprotkb/P40200/entry>, <https://www.ncbi.nlm.nih.gov/gene/10225>, <https://clinicaltrials.gov/study/NCT05565378> ;
  onco:tag "checkpoint-map" ;
  onco:targetClass "checkpoint" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16892>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153283>, <https://www.uniprot.org/uniprotkb/P40200/entry>, <https://www.ncbi.nlm.nih.gov/gene/10225> ;
  onco:related <https://onco.cc/targets/pvr/>, <https://onco.cc/targets/tigit/>, <https://onco.cc/drugs/dostarlimab/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/tigit-blockade/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/> .